PROPOFOL INJECTION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Propofol Injection Market Size and Forecast – 2025 to 2032

The global propofol injection market is estimated to be valued at USD 1.62 Bn in 2025 and is expected to reach USD 3.02 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.3% from 2025 to 2032. This significant growth reflects increasing demand for propofol injection in various medical procedures, driven by advancements in anesthesia and rising surgical procedures worldwide. The expanding healthcare infrastructure, especially in emerging markets, also plays a crucial role in the market expansion.

Key Takeaways of the Global Propofol Injection Market

• In 2025, generic are expected to dominate the global propofol injection market, capturing 64.5% of the market share.
• The largest segment within the market will be short-term sedation (procedural sedation), segment is projected to hold 42.3% of the market share in 2025.
• Single-dose vials are anticipated to lead the propofol injection market, accounting for a 38.9% share in 2025.
• North America is expected to lead the market, holding a share of 37.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with an estimated market share of 23.8% in 2025.

Market Overview

Market trends indicate a growing preference for safer, fast-acting anesthetics like propofol injections due to their rapid onset and quick recovery profiles. Innovations in formulation and delivery methods are enhancing patient safety and satisfaction, further boosting the demand. Additionally, increasing awareness about minimally invasive surgeries and rising investments in healthcare infrastructure continue to propel market growth. Regulatory approvals and ongoing clinical trials for newer indications of propofol also contribute to this upward trend in the global market.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Propofol Injection Market Insights, By Product Type - Generic Contributes the Highest Share of the Market Owning to Increasing Cost Sensitivity and Widespread Acceptance Among Healthcare Providers

The global market for propofol injection mainly consists of generic, which are expected to have a share of 64.5% in 2025. The primary reason for this is the growing focus on cost containment in the healthcare system across the globe. Every day hospitals and healthcare providers find ways to cut costs, and one of the areas they focus on is the procurement of essential and commonly used medicines such as propofol. Since generics cost less than branded formulations, they are usually the choice for hospitals and health providers.

In November 2024, the U.S. Food and Drug Administration approved PropofolVet Multidose, the first generic propofol injectable emulsion for dogs. Manufactured by Parnell Technologies Pty. Ltd., based in New South Wales, Australia, PropofolVet Multidose is designed for use as an injectable anesthetic in dogs

Propofol Injection Market Insights, By Application - Short-term Sedation (Procedural Sedation) Contributes the Highest Share of the Market due to Expanding Outpatient Surgical Procedures and Minimally Invasive Diagnostic Techniques

Short-term sedation (procedural sedation), will be the major segment in the propofol injection market with 42.3% in 2025, given mainly to the increased demand for outpatient and minimally invasive treatments. The quick onset of action and short duration, thus enabling fast recovery and efficient turnover, are main reasons for propofol being preferred in ambulatory care and day surgeries.

Its use has increased along with the acceptance of less invasive techniques like endoscopes and biopsies that require short-term sedation. Propofol's ability to prevent nausea after surgery also makes patients more comfortable and thus the drug is preferred over other sedatives.

Propofol Injection Market Insights, By Formulation - Single-Dose Vials Contribute the Highest Share of the Market Reflecting Enhanced Safety Protocols and Demand for Precise Dosing

The propofol injection market is expected to be predominantly composed of single-dose vials with a market share of 38.9% in 2025, because of their compliance with infection control policies and safety enhancement. Vials of this nature mitigate the chances of contamination which is very important in hospitals that are trying to prevent the occurrence of healthcare-associated infections (HAIs).

Furthermore, single-dose vials provide the exact amount of medicine needed which leads to less wastage of drugs and helps in the management of inventory especially in operating theatres where the exact administration of medication is crucial for the safety of the patient and the effectiveness of the sedation.

Regional Insights

To learn more about this report, Download Free Sample

North America Propofol Injection Market Analysis and Trends

In 2025, North America will account for 37.3% of the propofol injection market share, due to its excellent healthcare system. The region is also characterized by large-scale use of modern anesthetic agents in hospitals and outpatient surgical centers. The presence of top pharmaceutical companies like Pfizer, B. Braun Melsungen AG, and Fresenius Kabi not only guarantees a reliable supply chain but also the flow of new product development.

In May 2020, Hikma Pharmaceuticals announced the launch of Propofol Injectable Emulsion, USP, in response to the significant shortage caused by the COVID-19 pandemic. The product, available in 20 mL, 50 mL, and 100 mL vials, was launched in the United States to address increased demand for this critical medication, which had been added to the U.S. FDA's drug shortage list.

Asia Pacific Propofol Injection Market Analysis and Trends

The Asia Pacific region will be the largest and fastest-growing market for propofol injection with a 23.8% market share in 2025. The rapid uplift of health care infrastructure will be a significant factor as patient awareness is rising, and the number of operations is growing due to population increase and urbanization. Countries like India and China are giving their people better access to health care through various initiatives that include support for local drug manufacturing and distribution.

The market ecosystem consists of growing hospital establishments and increased foreign direct investment in healthcare that plays the role of a gut that keeps the market running. Players like Hetero Labs, Sun Pharmaceutical Industries, and Nichi-Iko Pharmaceutical Co., Ltd. are continuously expanding their production capacities and investing in subdivisions tailored to local needs, thus, speeding up market growth.

Global Propofol Injection Market Outlook for Key Countries:

U.S. Propofol Injection Market Analysis and Trends

The U.S. propofol injection market is backed up by a highly developed healthcare system which has led to the wide acceptance of propofol for anesthesia, sedation, and critical care use. The presence of significant companies like Pfizer, which was the original manufacturer of propofol formulations, is strong due to the backing of strong intellectual property and continuous improvements in product formulation. Regulatory agencies such as U.S. FDA set high safety standards that make physicians trust the product.

In April 2022, Avet Pharmaceuticals, a rapidly growing specialty pharmaceutical company based in East Brunswick, New Jersey, announced the U.S. launch of its generic Propofol Injectable Emulsion, USP 10 mg/mL, in 20-, 50-, and 100-mL single patient-use vials. The product, an AB-rated generic equivalent of DIPRIVAN, received U.S. FDA approval and will be distributed immediately to address the ongoing shortage in hospitals and surgical centers.

Germany Propofol Injection Market Analysis and Trends

Germany, with its sophisticated medical infrastructure, rigorous regulatory regime, and significant pharmaceutical manufacturing, is still the main player in Western Europe propofol injection market. The market is dominated by top European companies such as Fresenius Kabi, which has a wide range of products and a well-established distribution network. Government initiatives that concentrate on healthcare quality and patient safety help to stabilize the market. The country also acts as a strategic center for exporting to the EU member states that are adjacent to it, thanks to the uniform trade regulations and effective logistics.

In October 2020, Fresenius Kabi, a global healthcare company headquartered in Germany and specializing in injectable pharmaceuticals, introduced its first product with smart labels embedded with radio-frequency identification (RFID) technology Diprivan (Propofol) 200 mg per 20 mL Injectable Emulsion, USP. This innovation, now available in the U.S., is designed to improve medication inventory management by increasing accuracy, minimizing waste, and reducing labor costs.

Japan Propofol Injection Market Analysis and Trends

The high-quality propofol injection market in Japan, due to excellent clinical practices and a strong focus on pharmaceutical innovation. The companies involved, such as Nichi-Iko Pharmaceutical and Fuji Pharma, provide advanced formulations that are in line with local regulatory requirements. The Japanese government encourages healthcare innovations that lead to the use of anesthetics such as Propofol. The population is not increasing, but steady demand is maintained due to the elderly requiring more surgical and diagnostic interventions.

In February 2020, Maruishi Pharmaceutical Co., Ltd., a leading pharmaceutical company in Japan, announced the release of Propofol Intravenous Injection 1% 100mL "Maruishi." This anesthetic medication is primarily used for the induction and maintenance of general anesthesia, as well as for sedation during artificial respiration in intensive care. The product is designed to act on the GABAA receptors in the brain to produce its effects.

India Propofol Injection Market Analysis and Trends

India propofol injection market is on the path of rapid expansion due to the factors such as increasing healthcare awareness, opening private and government hospitals, and improving surgical procedures in both urban and rural areas. Indian pharmaceutical manufacturers like Sun Pharmaceutical and Hetero Labs are offering inexpensive propofol options to cater to the price-sensitive market, thus being the vital players in the market. The government's “Make in India” campaign and ease of doing business initiatives are also working in favor of local production and export.

For example, Dr. Reddy’s Laboratories, based in Hyderabad, India, announced the launch of its Propofol Injectable Emulsion, USP, a therapeutic equivalent to DIPRIVAN (propofol) Injectable Emulsion, USP, approved by the U.S. Food and Drug Administration (U.S. FDA). The product, available in 10 mg/mL vials for single patient use, aims to provide an affordable and innovative solution in anesthesia care.

End User Feedback and Unmet Needs in the Global Propofol Injection Market

• The fast onset and rapid recovery of propofol, especially in hospitals and outpatient centers, are highly appreciated by end users and thus marked as the best choice for such demanding environments. Anesthesiologists emphasize the significant control of sedation and related effects next to the usage of Propofol. Nonetheless, different reactions of patients to the drug are the main factors that complicate the adjustment of the dosage, particularly in outpatient settings where quick recovery is of utmost importance.
• On the other hand, users report that the existing customization options are inadequate to their needs, particularly regarding the size of vials and the possibility of using multi-dose for clinical applications. They also point out to affordability and consistent supply as issues that remain. The market could be opened up to growth, enhanced customer satisfaction and competition in innovation through the addressing of these concerns by provision of more personalized dosing and cost-effective options.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In April 2025, Avenacy, a specialty pharmaceutical company focused on providing critical injectable medications, announced the launch of Propofol Injectable Emulsion, USP in the U.S. propofol injection market as a therapeutic generic equivalent to Diprivan. The drug, approved by the U.S. FDA, is used for general anesthesia and sedation in various patient groups. Avenacy will offer the product in 200 mg/20 mL, 500 mg/50 mL, and 1,000 mg/100 mL vials.
• In January 2025, Parnell Technologies Pty LTD, a pet care products manufacturer focused on providing reliable high-quality solutions, announced the launch of PropofolVet Multidose, the first generic propofol injectable emulsion specifically for dogs. This new anesthetic offers veterinary practices a cost-effective, versatile option for both induction and maintenance of anesthesia in dogs, supporting short procedures and enhancing practice efficiency.
• In January 2025, Fresenius Kabi, a global healthcare company specializing in injectable pharmaceuticals, introduced smart labels with embedded +RFID technology for its Diprivan (Propofol) Injectable Emulsion, USP, 200 mg per 20 mL single-dose vials. The new labels are fully compatible with all major RFID kit and tray systems in the U.S., enhancing medication inventory efficiency and safety by eliminating the need for manual tagging.
• In August 2024, Amneal Pharmaceuticals, a leading generics manufacturer, received U.S. FDA approval for its propofol injectable emulsion single-dose vials, addressing longstanding supply issues. The approval includes 200mg/20 mL, 500mg/50 mL, and 1000mg/100 mL vials, providing a new source of this critical anesthetic drug.

Top Strategies Followed by Global Propofol Injection Market Players

• The leading companies in the market pour their money into R&D in order to come up with new propofol formulations that would not only perform but also meet the strictest regulatory and clinical needs. They are collaborating with OEMs and healthcare providers in forming alliances to broaden the product lines and strengthen their market share.
  • Baxter International & Fresenius Kabi are major player, known for its high-quality propofol formulations and strong R&D investment. The company partners with leading hospitals and healthcare providers to enhance its product offerings, ensuring regulatory compliance and high performance across various clinical settings.

• The other companies, which are placed in the middle of the propofol injection market, aim at the needs of price-sensitive consumers who need reliable but at the same time affordable anesthetic solutions. These companies make use of the low-cost production methods that allow them to keep their prices low and thus to acquire a competitive advantage while maintaining the quality required.
  • Mylan (now part of Viatris) is a good example of a mid-level player that targets price-sensitive consumers. Mylan focuses on providing reliable yet affordable anesthetic solutions in the propofol market. The company’s strategy involves leveraging cost-effective production methodologies to maintain competitive pricing while ensuring the quality and reliability of its products.

• The smallest companies that are often operating only in certain regions resort to niche strategies to obtain unique positions in the global market for propofol injection. The companies are primarily concerned with modern product characteristics like better stability, different formulations, or combined substances that make their products different from the usual ones.
  • Apotex, a smaller player operating regionally, is an example of a company that differentiates itself by focusing on niche strategies within the propofol injection sector. Apotex is known for offering innovative features such as alternative formulations and adjunctive compounds to enhance the stability and efficacy of their propofol products.

Market Report Scope

Propofol Injection Market Report Coverage

Propofol Injection Market Dynamics

To learn more about this report, Download Free Sample

Propofol Injection Market Driver - Increasing Prevalence of Chronic Diseases Requiring Surgeries

The rising occurrence of long-term diseases like heart problems, cancer, and diabetes is one of the main factors causing the demand for more surgical procedures all over the world and thus propofol injection sales are increasing. Since these diseases usually require very difficult surgeries or diagnostic methods that can only be done under general anesthesia, propofol with its rapid onset and recovery time has become the most preferred anesthetic among doctors. The aging world population continues to worsen the problem of chronic diseases and thus the need for surgeries becomes even more frequent.

For instance, in September 2025, the World Health Organization (WHO) reported a sharp rise in the global burden of chronic or noncommunicable diseases, which claimed around 43 million lives in 2021 accounting for 75% of non-pandemic-related deaths. The data highlighted cardiovascular diseases, cancers, chronic respiratory conditions, and diabetes as the leading causes, with 80% of premature deaths occurring in low- and middle-income countries.

Propofol Injection Market Opportunity - Expansion of Healthcare Facilities in Emerging Economies

The global propofol injection market will benefit a lot from the fast growing healthcare facilities in the developing economies such as India, China, Brazil, and Southeast Asian countries. These areas are seeing big investments in healthcare infrastructure which are largely supported by increasing government healthcare financing, population growth, and rising incidence of long-term and surgical conditions that need anesthesia management. The new setting up of hospitals, outpatient surgical centers, and diagnostic clinics is increasing the consumption of intravenous anesthetics like propofol, which is preferred for its quick effect, short duration, and good safety profile.

For instance, in March 2023, Kannapolis-based pharmaceutical startup Genixus announced plans to expand its manufacturing operations with the opening of a new facility in Concord. This expansion is aimed at meeting the growing demand for its first product, a ready-to-administer Propofol syringe, which launched in the fourth quarter of 2022. Genixus also plans to triple its headcount as part of its growth strategy.

Analyst Opinion (Expert Opinion)

• The propofol injection market is progressing at a solid pace, which is largely due to the influence of a couple of primary factors. Among these, the new technology advancements are the most noticeable, especially in the area of high-quality production, and that of better drug delivery systems, both of which are becoming much safer for the patient and more efficient in terms of anesthesia. Regulatory backing, mainly provided by organizations like the U.S. FDA and EMA, is setting up more stringent requirements and hence driving market players to pour in big bucks in R&D to comply with such standards as well as get ahead in the competition.
• On the other hand, the main reason for the gradual increase in throughput of production and eventually the market size is the rising customer preference for outpatient and day care surgeries, since with propofol anesthesia the patient can expect coming back to normal mostly without any side effects.
• Among the new propofol formulations that are going to be the game changers include smaller ampoules for a single dose and market-specific solutions. The events of the American Society of Anesthesiologists Annual Meeting and the European Society of Anesthesiology Congress are some of the major drivers of the growing knowledge-sharing and industry collaboration, which in turn shapes the trends in the industry and has a direct influence on future regulations and innovations in the propofol injection market.

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Generic
  • Branded
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Short-term Sedation (Procedural Sedation)
    • Endoscopy (Colonoscopy, Upper GI Endoscopy)
    • Bronchoscopy
    • Cardioversion
    • Minor Surgical Procedures
  • Long-term Sedation (Intensive Care Unit - ICU)
  • Induction and Maintenance of Anesthesia
• Formulation Insights (Revenue, USD Bn, 2020 - 2032)
  • Single-Dose Vials
  • Multi-Dose Vials
  • Pre-filled Syringes
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Clinics
  • Others (e.g., Recovery Centers)
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Fresenius Kabi
  • Baxter International
  • Braun Melsungen AG
  • AbbVie Inc.
  • Pfizer Inc.
  • Hikma Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz (a Novartis division)
  • Reddy’s Laboratories
  • Guangdong Jiabo Pharmaceutical
  • Xian Libang Pharmaceutical
  • Jiangsu Nhwa Pharmaceutical
  • Sinopharm Guorui Pharmaceutical
  • Midas Pharma
  • Emcure Pharmaceuticals

Sources

Primary Research Interviews

Industry Stakeholders

• Interviews with manufacturers, suppliers, distributors, and CEOs
• Surveys and questionnaires for decision-makers and Key Opinion Leaders (KOLs)

End Users

• Interviews with healthcare professionals and anesthesiologists
• Surveys targeting hospital procurement departments
• Discussions with ICU and surgical unit managers
• Feedback from outpatient surgery centers
• Consultations with pharmacy directors in healthcare settings
• Engagements with clinical trial coordinators

Government and International Databases

• U.S. Food and Drug Administration (FDA) Drug Approval Database
• World Health Organization (WHO) International Drug Monitoring Programme
• European Medicines Agency (EMA) Public Assessment Reports
• U.S. Drug Enforcement Administration (DEA) National Forensic Laboratory Information System (NFLIS)
• National Institutes of Health (NIH) ClinicalTrials.gov
• Indian Central Drugs Standard Control Organization (CDSCO)

Trade Publications

• Journal of Clinical Anesthesia
• Anesthesia & Analgesia
• British Journal of Anaesthesia
• International Journal of Clinical Pharmacology and Therapeutics
• Journal of Parenteral and Enteral Nutrition
• Pharmaceutical Technology

Academic Journals

• Clinical Pharmacokinetics and Pharmacodynamics of Propofol
• Novel Propofol Derivatives and Implications for Anesthesia
• Development and Optimization of Lipid-Based Self-Nanoemulsifying Drug Delivery System for Propofol
• Investigation Report on China's Propofol Market 2021-2025
• General Anesthesia Drugs Market Size to Reach USD 8,791 Million by 2034
• Propofol: Current Updates, Challenges, and Strategies for Anesthesia

Reputable Newspapers

• The New York Times
• The Guardian
• The Wall Street Journal
• Financial Times
• The Washington Post
• Economic Times

Industry Associations

• American Society of Anesthesiologists (ASA)
• European Society of Anaesthesiology (ESA)
• International Anesthesia Research Society (IARS)
• American Association of Nurse Anesthetists (AANA)
• Society of Critical Care Medicine (SCCM)
• Indian Society of Anaesthesiologists (ISA)

Public Domain Resources

• U.S. National Library of Medicine
• European Medicines Agency
• World Health Organization
• U.S. Drug Enforcement Administration
• National Institutes of Health
• Indian Central Drugs Standard Control Organization

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years